X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2017 November 12, 2017 argenx to Present at Upcoming Investor Conferences November 6, 2017 argenx announces results of extraordinary shareholders’ meeting 2017 November 1, 2017 argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017 October 29, 2017 argenx launches Phase I trial with subcutaneous formulation of ARGX-113 October 25, 2017 argenx reports third quarter 2017 financial results and September 25, 2017 argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris September 24, 2017 argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis September 21, 2017 Invitation to the extraordinary shareholders’ meeting September 19, 2017 argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia August 23, 2017 argenx reports second quarter business update and half-year 2017 financial results August 22, 2017 argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia August 16, 2017 argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017 Pagination First page « First Previous page ‹ Previous … Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Page 24 … Next page Next › Last page Last »